Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights.

Respiratory Research
Gregoire RuffenachMansoureh Eghbali

Abstract

Pulmonary hypertension (PH) developing secondarily in pulmonary fibrosis (PF) patients (PF-PH) is a frequent co-morbidity. The high prevalence of PH in PF patients is very concerning since the presence of PH is a strong predictor of mortality in PF patients. Until recently, PH was thought to arise solely from fibrotic destruction of the lung parenchyma, leading to hypoxic vasoconstriction and loss of vascular bed density. Thus, potential cellular and molecular dysregulation of vascular remodeling as a driver of PF-PH has been under-investigated. The recent demonstrations that there is no correlation between the severity of the fibrosis and development of PH, along with the finding that significant vascular histological and molecular differences exist between patients with and without PH have shifted the etiological paradigm of PF-PH. This review aims to provide a comprehensive translational overview of PH in PF patients from clinical diagnosis and outcome to the latest understanding of the histology and molecular pathophysiology of PF-PH.

References

Apr 1, 1968·The Journal of Pathology and Bacteriology·D HeathC F Hawkins
Jan 1, 1984·Respiration; International Review of Thoracic Diseases·J GłuskowskiJ Zieliński
Oct 28, 1999·Cardiovascular Research·A Y SaadjianR P Guieu
Jan 5, 2000·American Journal of Respiratory and Critical Care Medicine·M FartoukhG Simonneau
Dec 14, 2002·American Journal of Respiratory and Critical Care Medicine·Selim M ArcasoyRobert M Kotloff
May 30, 2003·American Journal of Respiratory and Critical Care Medicine·Harold R CollardKevin K Brown
May 30, 2003·American Journal of Respiratory and Critical Care Medicine·Kevin R FlahertyFernando J Martinez
Feb 3, 2004·American Journal of Respiratory and Critical Care Medicine·Masahito EbinaToshihiro Nukiwa
May 1, 2004·American Journal of Respiratory and Critical Care Medicine·Gregory P CosgroveG Scott Worthen
Jan 11, 2005·American Journal of Respiratory and Critical Care Medicine·Yangjin JegalThomas V Colby
Oct 21, 2005·Chest·Hassan F NadrousJay H Ryu
Dec 3, 2005·American Journal of Respiratory and Critical Care Medicine·Katia VaraniPier Andrea Borea
Mar 15, 2006·Transplantation·Gaëlle DauriatMichel Fournier
Jun 17, 2006·American Journal of Respiratory and Critical Care Medicine·David J LedererSteven M Kawut
Dec 19, 2006·Journal of the American College of Cardiology·Marius M HoeperLewis J Rubin
Jan 27, 2007·American Journal of Respiratory and Critical Care Medicine·Steven D NathanRubin M Tuder
Jul 3, 2007·Respiratory Medicine·David A ZismanArun S Karlamangla
Jul 13, 2007·The European Respiratory Journal·A F ShorrS D Nathan
Sep 18, 2007·Chest·Nina M PatelSteven M Kawut
Jan 25, 2008·Respiration; International Review of Thoracic Diseases·Steven D NathanKevin Leslie
Jan 24, 2009·American Journal of Respiratory and Critical Care Medicine·Micah R FisherPaul M Hassoun
Jul 11, 2009·Clinical Radiology·A Devaraj, D M Hansell
Sep 22, 2009·American Journal of Respiratory Cell and Molecular Biology·Naozumi HashimotoYoshinori Hasegawa
May 21, 2010·The New England Journal of Medicine·UNKNOWN Idiopathic Pulmonary Fibrosis Clinical Research NetworkGary W Hunninghake
Oct 6, 2010·Respirology : Official Journal of the Asian Pacific Society of Respirology·Tamera J CorteStephen J Wort
Nov 9, 2010·American Journal of Respiratory Cell and Molecular Biology·Laszlo FarkasMartin Kolb
Nov 9, 2010·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Claudia Grosse, Alexandra Grosse
Dec 3, 2010·Respirology : Official Journal of the Asian Pacific Society of Respirology·Afroditi K BoutouIoannis Stanopoulos

❮ Previous
Next ❯

Citations

May 18, 2021·Expert Opinion on Emerging Drugs·Giacomo SgallaLuca Richeldi
Jun 16, 2021·Current Opinion in Pulmonary Medicine·Jürgen Behr, Steven D Nathan

❮ Previous
Next ❯

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.